Table 3.
First remission treatment received by donor availability and randomized allocation
| Trial | Donor |
No donor |
|||||
|---|---|---|---|---|---|---|---|
| Sibling donor HCT | Autograft | Chemotherapy | Other | Auto-graft | Chemotherapy | Other | |
| Donor versus no donor (chemo) | |||||||
| MRC UKALLXA21 | 35 (74%) | 12 (26%) | 33 (38%) | 54 (62%) | |||
| PMH 9223 | 24 (71%) | 10 (29%) | 36 (100%) | ||||
| JALSG-ALL9324 | 22 (69%) | 10 (31%) | 5 (5%) | 75 (77%) | 17 (18%) | ||
| GRAALL 200325 | 38 (86%) | 6 (14%) | 60 (68%) | 28 (32%) | |||
| Donor v no donor (auto) | |||||||
| HOVON 18 ALL27 | 32 (89%) | 1 (3%) | 2 (6%) | 1 (3%) | 49 (84%) | 5 (9%) | 4 (7%) |
| GOELAL0228 | 32 (97%) | 1 (3%) | 80 (84%) | 15 (16%) | |||
| NILG ALL08/9629 | 11 (61%) | 7 (39%) | 17 (63%) | 10 (37%) | |||
| HOVON 37 ALL27 | 42 (78%) | 1 (2%) | 10 (19%) | 1 (2%) | 71 (67%) | 23 (22%) | 12 (11%) |
| Donor versus no donor (chemo/auto) | |||||||
| EORTC 0686111 | 43 (64%) | 23 (34%) | 1 (1%) | 28 (18%) | 121 (79%) | 4 (3%) | |
| UKALLXII/E299314 | 327 (72%) | 5 (1%) | 120 (26%) | 1 (0%) | 149 (20%) | 533 (72%) | 58 (8%) |
| PETHEMA ALL-9315 | 49 (70%) | 2 (3%) | 19 (27%) | 31 (37%) | 53 (63%) | ||
| LALA-9416 | 86 (74%) | 6 (5%) | 24 (21%) | 63 (36%) | 105 (60%) | 6 (3%) | |
| EORTC ALL-4/0695117 | 64 (69%) | 2 (2%) | 23 (25%) | 4 (4%) | 29 (24%) | 85 (71%) | 6 (5%) |
| Randomized arm |
Autograft (all patients) |
Chemotherapy (all patients) |
|||||
| EORTC 0686111 | 15 (63%) | 9 (38%) | 21 (100%) | ||||
| UKALLXII/E299314 | 136 (59%) | 84 (37%) | 9 (4%) | 2 (0%) | 222 (97%) | 4 (2%) | |
| PETHEMA ALL-9315 | 31 (62%) | 19 (38%) | 1 (2%) | 46 (96%) | 1 (2%) | ||
| LALA-9416 | 63 (73%) | 23 (27%) | 66 (100%) | ||||
| EORTC ALL-4/0695117 | 30 (75%) | 10 (25%) | 1 (3%) | 36 (97%) | |||
Ph+ patients have been excluded.